Results 71 to 80 of about 11,471 (211)

SCORTEN: A Severity-of-Illness Score for Toxic Epidermal Necrolysis

open access: yes, 2000
The mortality of toxic epidermal necrolysis is about 30%. Our purpose was to develop and validate a specific severity-of-illness score for cases of toxic epidermal necrolysis admitted to a specialized unit and to compare it with the Simplified Acute ...
Bastuji-Garin, Sylvie   +5 more
core   +1 more source

Deep cutaneous Trichosporon asahii infection in a patient recovering from toxic epidermal necrolysis

open access: yesMedical Mycology Case Reports, 2019
Patients with toxic epidermal necrolysis, a condition that causes full thickness epidermal necrosis that affects over 30% of the skin surface and mucosal membranes, often develop comorbid infections throughout the recovery of the disease [1].
John L. Kiley   +4 more
doaj   +1 more source

Systemic Therapy for Paediatric Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review of Current Evidence and Limitations

open access: yesJournal of Paediatrics and Child Health, EarlyView.
ABSTRACT Aim The role of systemic therapy in paediatric Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) remains undefined. Management is primarily guided by observational data and variable practice patterns. This systematic review aims to integrate recent evidence and evaluate clinical outcomes associated with systemic therapies in ...
Samantha Ting   +3 more
wiley   +1 more source

Toxic epidermal necrolysis

open access: yesPhilippine Journal of Ophthalmology, 2011
Objective: To recognize the common ocular signs and symptoms of toxic epidermal necrolysis (TEN), differentiate it from similar diseases, give the appropriate management, and provide continuity of care.
Rosalie Mae M. Reyes, MD   +1 more
doaj  

Inflammation Unchecked: Concurrent Kawasaki Disease and Stevens‐Johnson Syndrome in an 18‐Month‐Old Child

open access: yes
Arthritis Care &Research, EarlyView.
Catherine Deffendall   +6 more
wiley   +1 more source

Development of Multidisciplinary Consensus‐Informed Guidance for the Management of Paediatric Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Among Clinicians From Australasian Tertiary Referral Hospitals

open access: yesJournal of Paediatrics and Child Health, EarlyView.
ABSTRACT Background Paediatric Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a rare, severe mucocutaneous reaction requiring coordinated multidisciplinary care. Existing guidelines provide evidence‐based recommendations, but implementation across tertiary paediatric hospitals requires practical consensus on local resources.
Patrick David Mahar   +32 more
wiley   +1 more source

Toxic epidermal necrolysis associated with severe cytomegalovirus infection in a patient on regular hemodialysis.

open access: yesMediterranean Journal of Hematology and Infectious Diseases, 2011
Primary illness with cytomegalovirus leads to latent infection with possible reactivations especially in the immunocompromised patients. Toxic epidermal necrolysis is an immune mediated cytotoxic reaction.
Dina Khalaf   +3 more
doaj   +1 more source

Leveraging Administrative Health Data to Capture Rare Adverse Drug Reactions: Identifying Pediatric Patients With Trimethoprim‐Sulfamethoxazole Acute Respiratory Distress Syndrome

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Rare adverse drug reactions (ADRs) are underrecognized and underreported in the electronic medical record (EMR). These events often require clinical review, making systematic identification challenging. The study aim was to develop an approach to prioritize identification and validation of a rare ADR to trimethoprim‐sulfamethoxazole causing ...
Keith Feldman   +6 more
wiley   +1 more source

Toxic epidermal necrolysis: A review

open access: yesJournal of the American Academy of Dermatology, 1991
This article reviews the many facets of toxic epidermal necrolysis. Emphasis is placed on the importance of early diagnosis, burn unit placement, supportive care, and avoidance of systemic steroids. Discussion also includes other therapeutic options and the pathophysiology of the disease.
From the College of Pharmacy, the Division of Dermatology and Cutaneous Surgery ( host institution )   +4 more
openaire   +3 more sources

Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant‐Ineligible Newly Diagnosed Myeloma: An Australian Real‐World, Multicenter Study

open access: yesAsia-Pacific Journal of Clinical Oncology, Volume 22, Issue 4, Page 573-583, August 2026.
RVD with weekly bortezomib dosing in real‐world newly diagnosed transplant‐ineligible myeloma shows comparable efficacy and reduced toxicity compared to twice‐weekly trial protocols. ABSTRACT Background Lenalidomide, bortezomib, and dexamethasone (RVD) remains a standard of care regimen for newly diagnosed multiple myeloma in centers without access to ...
Samantha Kurniawan   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy